Sarcomas

Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.

Sarcoma management demands coordinated, subtype-specific care and treatment sensitivities delivered by a dedicated multidisciplinary team.

Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.

Ris-rez improved PFS vs chemotherapy in the ARTEMIS-011 trial for relapsed/refractory osteosarcoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

R. Lor Randall, MD, FACS, reviews a longitudinal study in osteosarcoma showing a strong correlation between ctDNA status and clinical outcomes such as EFS.

Afami-cel received full FDA approval for unresectable or metastatic synovial sarcoma after prior chemotherapy.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

The FDA has accepted a BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.

Varegacestat reduced the risk of disease progression or death by 84% vs placebo in progressing desmoid tumors.

Circulating tumor DNA analyses from the phase 1/1b StrateGIST-1 trial also support baseline ctDNA detectability as a potentially prognostic marker in this population.

Abemaciclib markedly improved PFS vs placebo in patients with advanced dedifferentiated liposarcoma.

Bezuclastinib plus sunitinib decreased the risk of progression or death by 50% compared with sunitinib monotherapy in GIST.

The FDA has accepted for review an NDA for bezuclastinib plus sunitinib in imatinib-pretreated GISTs, with a PDUFA date of November 30, 2026.

The PD-1/antiangiogenic combination yielded a 24% ORR and 28-month median PFS, surpassing prior monotherapy benchmarks in refractory chordoma.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.

R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies such as pimicotinib in TGCT enables a tumor biology–informed approach to care.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

An NDA seeking the approval of varegacestat for the treatment of adult patients with desmoid tumors has been submitted to the FDA.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

The CSF-1R–targeting monoclonal antibody emactuzumab met key end points in the phase 3 TANGENT study, setting the stage for a BLA submission.